Jasper Hellweg
Stock Analyst at Argus Research
(2.73)
# 1,951
Out of 4,876 analysts
89
Total ratings
50.7%
Success rate
17.45%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Downgrades: Hold | n/a | $126.08 | - | 4 | Apr 4, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $284.27 | +40.71% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $94.79 | +58.24% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $47.85 | +25.39% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $521.00 | +124.57% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $441.30 | +24.63% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $69.85 | +21.69% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $68.51 | +82.46% | 1 | Feb 1, 2024 | |
| MRNA Moderna | Maintains: Buy | $160 → $140 | $27.16 | +415.46% | 4 | Sep 13, 2023 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $182.31 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $200 | $156.17 | +28.07% | 6 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $16.76 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $157.47 | +84.16% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $122.56 | -18.41% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $260.59 | +13.20% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $6.35 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $177.83 | -24.08% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $30.39 | - | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $26.54 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $256.14 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $114.15 | - | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $40.47 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $379.30 | -59.14% | 3 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $172.33 | -47.77% | 1 | Sep 19, 2018 |
Biogen
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $126.08
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $284.27
Upside: +40.71%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $94.79
Upside: +58.24%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $47.85
Upside: +25.39%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $521.00
Upside: +124.57%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $441.30
Upside: +24.63%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $69.85
Upside: +21.69%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $68.51
Upside: +82.46%
Moderna
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $27.16
Upside: +415.46%
AbbVie
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $182.31
Upside: -
Jun 17, 2022
Maintains: Buy
Price Target: $225 → $200
Current: $156.17
Upside: +28.07%
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $16.76
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $157.47
Upside: +84.16%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $122.56
Upside: -18.41%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $260.59
Upside: +13.20%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $6.35
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $177.83
Upside: -24.08%
Sep 4, 2020
Downgrades: Hold
Price Target: n/a
Current: $30.39
Upside: -
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $26.54
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $256.14
Upside: -
Mar 24, 2020
Downgrades: Hold
Price Target: n/a
Current: $114.15
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $40.47
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $379.30
Upside: -59.14%
Sep 19, 2018
Maintains: Buy
Price Target: $85 → $90
Current: $172.33
Upside: -47.77%